Genmab A (GMAB) Net Income towards Common Stockholders (2018 - 2026)

Genmab A's Net Income towards Common Stockholders history runs 6 years deep, the most recent figure standing at $5.7 billion for Q1 2026.

• Quarterly Net Income towards Common Stockholders rose 7.29% year-over-year to $5.7 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.1 billion (up 1.08% YoY) and the FY2025 annual result came in at $963.0 million, down 81.25% from the prior year.
• Net Income towards Common Stockholders was $5.7 billion for Q1 2026 at Genmab A, down from $5.8 billion in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $5.8 billion in Q3 2025 and bottomed at $556.0 million in Q2 2024.
• A 3-year average of $3.6 billion and a median of $4.8 billion in 2024 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2025 — Net Income towards Common Stockholders advanced 19.99% — and 2026, when it increased 7.29%.
• Genmab A's Net Income towards Common Stockholders stood at $1.3 billion in 2024, then surged by 333.71% to $5.8 billion in 2025, then retreated by 1.2% to $5.7 billion in 2026.
• Business Quant data shows GMAB's Net Income towards Common Stockholders at $5.7 billion in Q1 2026, $5.8 billion in Q3 2025, and $667.0 million in Q2 2025.